CTOs on the Move

Boston Immune Technologies and Therapeutics

www.bostonimmunetech.com

 
Boston Immune Technologies & Therapeutics based Inc
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Boston Immune Technologies and Therapeutics raised $10M on 03/17/2021

Similar Companies

GTC Biotherapeutics

GTC Biotherapeutics is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

INVO Bioscience

INVO Bioscience is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our INVOcell® Culture Device is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman`s body, in vivo. This revolutionary device promotes in vivo conception. It is an FDA cleared Intravaginal Culture (IVC) device that is a safe, effective and economical fertility treatment.

RNAimmune

RNAimmune is a biotechnology startup in the field of messenger RNA (mRNA) technology with more than 20 years expertise in handling and optimizing this versatile molecule for medical purposes. The principle of RNAimmune`s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines.

Med Fusion

Med Fusion is a Lewisville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.